White Paper on Ophthalmic Imaging for Choroidal Nevus Identification and Transformation into Melanoma.


Journal

Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919

Informations de publication

Date de publication:
05 02 2021
Historique:
entrez: 18 5 2021
pubmed: 19 5 2021
medline: 29 6 2021
Statut: ppublish

Résumé

To discuss the evolution of noninvasive diagnostic methods in the identification of choroidal nevus and determination of risk factors for malignant transformation as well as introduce the novel role that artificial intelligence (AI) can play in the diagnostic process. White paper. Longstanding diagnostic methods to stratify benign choroidal nevus from choroidal melanoma and to further determine the risk for nevus transformation into melanoma have been dependent on recognition of key clinical features by ophthalmic examination. These risk factors have been derived from multiple large cohort research studies over the past several decades and have garnered widespread use throughout the world. More recent publications have applied ocular diagnostic testing (fundus photography, ultrasound examination, autofluorescence, and optical coherence tomography) to identify risk factors for the malignant transformation of choroidal nevus based on multimodal imaging features. The widespread usage of ophthalmic imaging systems to identify and follow choroidal nevus, in conjunction with the characterization of malignant transformation risk factors via diagnostic imaging, presents a novel path to apply AI. AI applied to existing ophthalmic imaging systems could be used for both identification of choroidal nevus and as a tool to aid in earlier detection of transformation to malignant melanoma. Advances in AI models applied to ophthalmic imaging systems have the potential to improve patient care, because earlier detection and treatment of melanoma has been proven to improve long-term clinical outcomes.

Identifiants

pubmed: 34003909
pii: 2772292
doi: 10.1167/tvst.10.2.24
pmc: PMC7900849
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

24

Références

Ophthalmology. 1995 Sep;102(9):1351-61
pubmed: 9097773
Ophthalmology. 2008 Jun;115(6):1102-1102.e1
pubmed: 18519073
Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2297s-2300s
pubmed: 16609048
Ophthalmology. 2005 Oct;112(10):1784-9
pubmed: 16154197
Br J Ophthalmol. 2019 Oct;103(10):1441-1447
pubmed: 30523045
J Am Acad Dermatol. 2017 Nov;77(5):938-945.e4
pubmed: 28864306
Saudi J Ophthalmol. 2018 Jan-Mar;32(1):28-32
pubmed: 29755268
Ophthalmology. 2006 May;113(5):887-8.e1
pubmed: 16650691
Arch Dermatol. 2005 Aug;141(8):1032-4
pubmed: 16103334
Br J Ophthalmol. 2019 Feb;103(2):167-175
pubmed: 30361278
Arch Ophthalmol. 1992 Feb;110(2):245-50
pubmed: 1531290
Arch Ophthalmol. 1998 May;116(5):645-50
pubmed: 9596501
Ophthalmology. 2008 Mar;115(3):546-552.e2
pubmed: 18067966
Arch Ophthalmol. 2009 Aug;127(8):989-98
pubmed: 19667335
Arch Ophthalmol. 2000 Mar;118(3):360-4
pubmed: 10721958
Arch Ophthalmol. 2009 Mar;127(3):314-9
pubmed: 19273796
Retina. 2019 Oct;39(10):1852-1860
pubmed: 30883534
Ophthalmology. 2015 Oct;122(10):2071-83
pubmed: 26255109
Curr Opin Ophthalmol. 2019 May;30(3):206-214
pubmed: 30844944
Br J Ophthalmol. 2012 Nov;96(11):1443-4
pubmed: 22872672
Br J Ophthalmol. 2020 Feb;104(2):194-201
pubmed: 31023712
Ophthalmology. 2017 May;124(5):609-618
pubmed: 28159380
Nat Biomed Eng. 2018 Mar;2(3):158-164
pubmed: 31015713
Br J Ophthalmol. 1989 Nov;73(11):911-7
pubmed: 2605146
Retina. 2019 Oct;39(10):1840-1851
pubmed: 30608349
Ophthalmology. 2011 Dec;118(12):2468-73
pubmed: 21820181
Cancer. 2004 Nov 1;101(9):2067-78
pubmed: 15372475
Ophthalmology. 2011 Feb;118(2):382-8
pubmed: 20801518
J Am Acad Dermatol. 2001 Feb;44(2):207-18
pubmed: 11174377
Prog Retin Eye Res. 2018 Nov;67:1-29
pubmed: 30076935
Arch Ophthalmol. 2009 Aug;127(8):981-7
pubmed: 19667334

Auteurs

Carol L Shields (CL)

Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA.

Sara E Lally (SE)

Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA.

Lauren A Dalvin (LA)

Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA.

Mandeep S Sagoo (MS)

Ocular Oncology Service, Moorfields Eye Hospital and NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital and University College London Institute of Ophthalmology, London, UK.

Marco Pellegrini (M)

Eye Clinic, Department of Biomedical and Clinical Science "Luigi Sacco", Luigi Sacco Hospital, University of Milan, Milan, Italy.

Swathi Kaliki (S)

The Operation Eyesight Universal Institute for Eye Cancer, LV Prasad Eye Institute, Hyderabad, India.

Ahmet Kaan Gündüz (AK)

Department of Ophthalmology, Ankara University School of Medicine, Ankara, Turkey.

Minoru Furuta (M)

Department of Ophthalmology, Fukushima Medical University, Fukushima, Japan and Department of Ophthalmology, Yachiyo Medical Center, Tokyo Women's Medical University, Tokyo, Japan.

Prithvi Mruthyunjaya (P)

Ocular Oncology Service, Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.

Adrian T Fung (AT)

Westmead and Central Clinical Schools, Discipline of Clinical Ophthalmology and Eye Health, University of Sydney, Australia and Department of Ophthalmology, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia.

Jay S Duker (JS)

New England Eye Center, Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA.

Sara M Selig (SM)

Melanoma Research Foundation, Washington, DC, USA.

Antonio Yaghy (A)

Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA.

Sandor R Ferenczy (SR)

Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA.

Malvina B Eydelman (MB)

Office of Ophthalmic, Anesthesia, Respiratory, Ear, Nose and Throat (ENT), and Dental Devices, Food & Drug Administration (FDA), Washington, DC.

Mark S Blumenkranz (MS)

Department of Ophthalmology, Ophthalmology Innovation Program, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH